Humphreys Sophia Z
Providence St Joseph Health, Renton, WA 98057, USA.
Future Oncol. 2022 May;18(16):1997-2006. doi: 10.2217/fon-2021-1584. Epub 2022 Mar 17.
Biosimilars have introduced new opportunities to reduce the disproportionately high US healthcare spending on biologic medications. This article describes strategic utilization management program initiatives designed to promote biosimilar utilization, reduce biologic drug costs and increase sustainability in a US nonprofit health system. Key components of these biosimilar utilization management program initiatives included expedited procedures to evaluate and establish the formulary status of biosimilars, enhanced contracting negotiations, specially designed electronic medical record tools to guide physician prescribing, payer coverage analysis, evaluations of biologic-utilization trends and financial performance analysis. Within 2 years (2019-2020), this program has resulted in savings of USD$26.9 million for Providence St Joseph Health and biosimilar adoption rates that greatly exceed the US national average.
生物类似药为降低美国医疗保健在生物制剂上过高的不成比例支出带来了新机遇。本文描述了旨在促进生物类似药使用、降低生物药成本并提高美国一家非营利性医疗系统可持续性的战略利用管理计划举措。这些生物类似药利用管理计划举措的关键组成部分包括评估和确定生物类似药处方集地位的快速程序、加强合同谈判、专门设计的用于指导医生开处方的电子病历工具、支付方覆盖范围分析、生物制剂使用趋势评估以及财务绩效分析。在两年内（2019 - 2020年），该计划为普罗维登斯圣约瑟夫健康集团节省了2690万美元，且生物类似药的采用率大大超过美国全国平均水平。
